Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 31 от 222

Набира участници Фаза 2/3

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Kidney Transplant Rejection

The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 years who have low-to-moderate immunologic risk of graft rejection and receive their first kidney transplant are eligible if they meet all inclusion and no exclusion criteria. Study details include: * The study and treatment duration will be up to approximately 5 years. * The number of visits will be approximately 38.

Начало: 13.03.2026 Край: 15.08.2033 Възраст: 18–70 г. Лечение

Australia, China Sanofi NCT07412470

Набира участници Фаза 1/2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Carcinoma, Renal Cell Advanced Renal Cell Carcinoma Renal Cancer Renal Neoplasm +9

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

Начало: 12.03.2026 Край: 01.11.2028 Възраст: от 18 г. Лечение

Australia, Japan, United States Pfizer NCT07227415

Набира участници

Enhancing Health in Rural Populations: Music as Therapy

Stress Generalized Anxiety Chronic Pain Depression Disorder

The goal of this clinical trial is to learn whether a music-based intervention can improve mental and physical health and strengthen coping skills among adults living in residential care settings in northern Arizona. The main questions it aims to answer are: Does participation in the music-based intervention reduce stress, anxiety, depression, and pain?, and Does participation increase the use of music as a coping strategy and improve overall well-being? Researchers will compare participants' pre-intervention and post-intervention responses to determine whether the music classes are associated with improvements in health and coping outcomes. Participants will: Attend a 6-week music class held once per week for one hour; participate in active music activities such as drumming and rhythm exercises; complete a brief survey before and after the intervention. Some participants are also invited to complete a short interview about their experiences.

Начало: 12.03.2026 Край: 30.05.2027

United States Northern Arizona University NCT07538427

Набира участници

Short and Long-term Responses of PD Symptoms to Earstim

PARKINSON DISEASE (Disorder)

This is a prospective, multicenter, randomized, two-period study designed to evaluate the safety and effectiveness of the EarStim System for intermittent relief of motor symptoms in patients with Parkinson's disease experiencing wearing-off phenomena. Adult patients with moderate to severe Parkinson's disease (MDS-UPDRS Part III score ≥33) receiving oral dopaminergic therapy will be enrolled. Period A is a randomized, double-blind, sham-controlled phase conducted in a clinical setting. Period B is an unblinded, standard-of-care-controlled phase evaluating the effectiveness of the EarStim System during home use over 90 days.

Начало: 12.03.2026 Край: 01.02.2027 Възраст: от 44 г.

Turkey (Türkiye) Stoparkinson Healthcare Systems LLC NCT07400731

Набира участници

Turkish Adaptation of a Sleep Screening Tool for Pediatric Complex Chronic Conditions

Chronic Conditions Pediatric Intensive Care Sleep Disorder (Disorder) Sleep

This study aims to adapt the Sleep Screening Scale for Children and Adolescents with Complex Chronic Conditions (SCAC) into Turkish and test its reliability and validity for this population. Children and adolescents with complex chronic conditions (CCC) often have ongoing and multiple health problems. These children often face a high risk of sleep problems, but there are no screening tools in Turkish designed specifically for them. The main goal is to confirm that the Turkish version of the SCAC is accurate and reliable. The study will also look at how common different types of sleep problems are in children with CCC, and how these problems are related to factors such as diagnosis, age, sex, and other medical conditions. Another goal is to compare children's sleep at home with their sleep during a stay in the pediatric intensive care unit (PICU). The study will also examine how environmental factors (such as light and noise) and medical factors (such as pain, medications, and devices) affect sleep in the hospital. After discharge, sleep recovery will be followed for up to 3 months using sleep diaries and actigraphy (a wearable device that measures movement during sleep).

Начало: 12.03.2026 Край: 01.06.2027 Възраст: 1–18 г.

Turkey (Türkiye) Marmara University NCT07210476

Набира участници Фаза 1

Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease

Relapsed/Refractory Hematologic Autoimmune Disease

Trial status: Authorised

Начало: 12.03.2026 Възраст: от 18 г.

Germany, Spain CRISPR Therapeutics AG 2025-523845-90-00

Набира участници

QT-Digital Mental Health Engagement Study

Engagement, Patient

Sexual and gender minority (SGM) populations are disproportionately impacted by mental health concerns relative to their heterosexual and cisgender peers. Despite high need, SGM populations continue to report unmet mental health needs because they cannot or do not access mental health services. Digital Mental Health (DMH) services have been recognized as feasible, economical, and effective options to broaden the availability of mental health care to consumers who face barriers to mental health help-seeking. SGM consumers cite a preference for DMH care and this delivery format holds promise to attend to major mental health care access barriers experienced by this consumer group. Yet, the availability of DMH services tailored to the needs of SGM consumers is limited, and a dearth of research examines SGM populations' actual engagement with DMH services. A potential solution to fully understand how SGM populations utilize DMH services would be to characterize their engagement within a natural setting. Leveraging an established partnership with Mental Health America (MHA), a non-profit mental health advocacy group offering free, evidence-based screenings and self-guided DMH resources, this study will follow a large, naturalistic sample of SGM DMH consumers with the aim to test tailored engagement strategies with SGM DMH consumers using a micro-randomized trial (MRT) design. Results of this study will inform if delivering engagement strategies can meaningfully increase initial and sustained engagement with MHA resources and which types of strategies, specifically, work best for which users.

Начало: 12.03.2026 Край: 01.05.2027 Възраст: от 14 г.

United States University of Washington NCT07278765

Набира участници Фаза 1

Study of BW-50218 in Healthy Participants

Healthy Participants Study

Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants

Начало: 12.03.2026 Край: 30.06.2027 Възраст: 18–65 г. Лечение

Australia Shanghai Argo Biopharmaceutical Co., Ltd. NCT07401472

Набира участници Фаза 2

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Anal Carcinoma Cervical Carcinoma Malignant Female Reproductive System Neoplasm Rectal Carcinoma +2

This phase II trial tests the feasibility and side effects of vaginal DHEA to improve vaginal health after radiation for women with gynecologic, anal or rectal cancer. Treatment of cancers with radiation to the abdomen can influence the vaginal microbiome (any bacteria, virus, or other organisms found in the vagina). Both menopause and radiation cause a decrease in lubrication and elasticity of the vagina and symptoms including vaginal dryness, vaginal burning and itching, vaginal bleeding, pain or burning during urination, and pain during sexual intercourse. DHEA is a type of hormone replacement therapy. It is use to improve symptoms in women during menopause and may be effective in treating these symptoms for women who have received radiation.

Начало: 12.03.2026 Край: 31.12.2026 Възраст: от 50 г.

United States Ohio State University Comprehensive Cancer Center NCT07407647

Набира участници Фаза 1

Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers

High Cholesterol

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects

Начало: 12.03.2026 Край: 01.07.2027 Възраст: 18–65 г. Лечение

Australia Ikaria Bioscience Pty Ltd NCT07347678

Набира участници Фаза 3

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Начало: 12.03.2026 Край: 14.10.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +30 Bristol-Myers Squibb NCT07361510

Набира участници

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Stargardt Disease Retinitis Pigmentosa (RP) Inherited Retinal Degeneration

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa). Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.

Начало: 12.03.2026 Край: 01.03.2031 Възраст: от 18 г. Лечение

Australia Science Corporation NCT07266584

Набира участници Фаза 1/2

Stem Cell Therapy for Early Alzheimer's Disease

Cognitive Dysfunction

The goal of this clinical trial is to learn if stem cell therapy works to treat brain inflammation in adults. Inflammation in the brain may be involved in adults who have memory or thinking problems. The stem cells will be taken from participant's fat samples, processed and given back to participants, so they are their own donor. The main questions this trial aims to answer are: * Does stem cell therapy reduce inflammation in the brain? * Does stem cell therapy improve brain activity? * Does stem cell therapy slow down progression to Alzheimer's disease? Participants will: * Have a small fat biopsy taken at a doctor's office to process stem cells * Receive 4 infusions of stem cells, through a vein in the arm over 12 weeks * Visit the clinic every 2-4 weeks for the first 4 months and then every 1-2 months for 8 months for checkups and tests

Начало: 11.03.2026 Край: 01.01.2028 Възраст: 60–80 г.

United States Paul E Schulz NCT06775964

Набира участници

Structured Review: To Optimise Management and Prevent Harm in COPD

COPD

Background: Chronic obstructive pulmonary disease (COPD) is a serious lung condition and the third leading cause of death worldwide. People with COPD have sudden and distressing flare-ups (exacerbations). These can be triggered by infections or occur without a clear cause. Flare-ups often lead to hospital admission, can cause a lasting health decline, increase the risk of dying and are strongly liked to lower income. Sometimes, people are wrongly diagnosed with COPD, when they have a different health issue. Other diseases (like heart conditions) are common in people with COPD, and share similar symptoms. These have often not been diagnosed and worsening of these conditions can look like a flare-up of COPD, leading to incorrect treatment. Additionally, many people with COPD have not been offered appropriate treatments that would reduce their flare-up frequency. COPD flare-ups are treated with steroid tablets (prednisolone), and sometimes antibiotics. Frequent use of prednisolone causes side effects such as weight gain, bone thinning (osteoporosis) and diabetes. Reducing how often people with COPD have flare-ups can reduce these side effects. The investigators aim to reduce COPD flare-ups and prevent harm from prednisolone by improving the treatment of COPD, while also checking for other health conditions. The goal: In people with COPD, who take prednisolone for flare-ups (three of more times a year), the investigators want to see if a thorough assessment (that focuses on the treatment of COPD and diagnosis of other common health problems), reduces the number of flare-ups that need prednisolone over the next year. Design: Participants will attend a half-day hospital visit for a thorough check-up (a mini-MOT). The assessment includes a review by a doctor, questionnaires, blood tests, breathing tests, a scan of the chest (CT), and investigations on the heart. The investigators will make sure participants receive the correct treatment for their COPD. The assessment will focus on three areas: lung health, identifying and treating important health issues outside of the lungs (that may be contributing or causing symptoms similar to COPD) and supporting changes in behaviours that can improve lung health. These factors (whether in the lungs, body or related to lifestyle) are known as treatable traits. The investigators will also review participants prednisolone use and check for health problems that may have been caused by it. At the end of the assessment participants will be given a personalised treatment plan. Participants will be followed up for 12 months, at 3 month intervals. During this time they will collect information on the number of emergency hospital visits, serious heart-related events, steroid tablets taken for COPD flare-ups and any deaths. They will ask participants to complete short questionnaires about their health and wellbeing. Who provided advise on this study : Preventing COPD flare-ups is a top priority, identified by The James Lind Alliance (a national research priority setting partnership). This study was reviewed by the Northumbria Lung Research Patient Advisory Group (people living with COPD). They felt the study was well-designed and likely to make a meaningful difference. People with experience in research and COPD also gave feedback, and changes were made, such as reducing travel requirements, based on their views. The research team has successfully completed studies that have led to real improvement in COPD care, and are committed to ensuring this study has a similar positive impact. Sharing results: At the end of the study results will be shared with the public, study participants, healthcare workers, commissioners and guideline advisory groups. The findings will be shared on online platforms, present them at national/international conferences, and published in medical journals. The aim is to ensure findings improve clinical practice, policies and guidelines.

Начало: 11.03.2026 Край: 02.03.2029 Възраст: от 35 г.

United Kingdom Northumbria Healthcare NHS Foundation Trust NCT07460154

Набира участници

Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES)

Direct Care Workers Dementia Caregiver In-Home Care Caregiver Social Support +1

The VR-CARES project is an innovative, collaborative effort that invites dementia care professionals into the design process of a virtual reality platform seeking to mitigate their work-related burden and social isolation by cultivating a virtual community of support. The co-created, caregiver-specific VR platform will serve as a safe, communal space where caregivers can remotely connect with their peers, share fun experiences together, access support, learn self-care and build resilience within a supportive virtual network to enhance their social and mental health and job satisfaction. Central to VR-CARES in the principle of user-led innovation, ensuring that the technology not only serves but is informed and successfully adopted by the very individuals it intends to benefit, an important standard for empathetic and inclusive technology in healthcare.

Начало: 11.03.2026 Край: 01.10.2026 Възраст: от 18 г.

United States Rendever, Inc. NCT07430371

Набира участници Фаза 2

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

Начало: 11.03.2026 Край: 30.07.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +2 Hoffmann-La Roche NCT07287150

Набира участници Фаза 1/2

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Urothelial Cancer Advanced/Metastatic Urothelial Cancer Urothelial Carcinoma

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer. To join the study, participants must: * Be adults (18 years or older) and * Have locally advanced or metastatic urothelial cancer, The study has two groups: * Cohort A: People who have already received treatment for their cancer will get the study medicine ( PF-08634404) alone. * Cohort B: People who have not had treatment before will get the study medicine along with another cancer medicine called enfortumab vedotin. Everyone in the study will get the study medicine through a vein (IV infusion) with or without enfortumab vedotin. Treatment will continue as long as it helps and side effects are manageable. Before starting, participants will go through a screening period to check if they are eligible. During the study, they will have regular visits for treatment, health checks, and tests to see how the cancer is responding. Scans will be done regularly to monitor the cancer. If the cancer gets worse but the treatment is still helping and side effects are manageable, participants may be allowed to continue treatment with their doctor's and the sponsor's agreement.

Начало: 11.03.2026 Край: 05.09.2028 Възраст: от 18 г. Лечение

Australia, Japan, Puerto Rico +1 Pfizer NCT07421700

Набира участници Фаза 1

A Dose-Escalation Study of RO7875913 in Healthy Participants

Healthy Volunteers

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.

Начало: 11.03.2026 Край: 31.12.2026 Възраст: 18–65 г. Лечение

New Zealand Genentech, Inc. NCT07342114

Набира участници Фаза 2

INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS

High grade malignant brain neoplasm

Trial status: Authorised Number of AEs and SAEs per NCI-CTCAE criteria in first 12 weeks after DNX-2401 administration., Time to response., Duration of response., PFS, OS: 6- and 12- month PFS and OS rates., LPS/KPS and QoL (PedsQL™ Generic Score Scale) parameters compared to baseline. Overall response rate (ORR), defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD for at least 12 weeks) as best response according to RAPNO criteria.

Начало: 11.03.2026 Възраст: 18–64 г.

Netherlands, Spain Clinica Universidad De Navarra 2024-515009-24-00

Набира участници Фаза 2

Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study

Sjögren's syndrome

Trial status: Authorised - Change from baseline in ESSDAI score at Week 12, 24 and 36 (11)., - Proportion of patients achieving ≥3 points reduction from baseline in ESSDAIscore at Week 12, 24 and 36., - Proportion of patients achieving ESSDAI

Начало: 11.03.2026 Възраст: от 18 г.

Netherlands Radboud universitair medisch centrum Stichting 2024-519884-16-00

1 … 29 30 31 32 33 … 222